| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| 2413.T - M3, Inc. | HOLD | 0 @ JPY 11.2601 | JPY 0 | The current share valuation price of 2413.T based on adjusted close was JPY 11.2601. The average price that 2413.T shares were previous bought at was JPY 13.9573. The current market price is -19.3% lower than average price they were purchased at. The value of the holding in 2413.T has increased by JPY 5,022 (USD $32) compared to the previous valuation of M3, Inc. however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| 4151.T - Kyowa Kirin Co., Ltd. | HOLD | 0 @ JPY 15.206 | JPY 0 | The current share valuation price of 4151.T based on adjusted close was JPY 15.206. The average price that 4151.T shares were previous bought at was JPY 16.0268. The current market price is -5.1% lower than average price they were purchased at. The value of the holding in 4151.T has fallen by JPY 12,513 (USD $80) compared to the previous valuation of Kyowa Kirin Co., Ltd. |
| 4502.T - Takeda Pharmaceutical Company Limited | HOLD | 0 @ JPY 35.3138 | JPY 0 | The current share valuation price of 4502.T based on adjusted close was JPY 35.3138. The average price that 4502.T shares were previous bought at was JPY 29.6131. The current market price is 19.3% higher than average price they were purchased at. The value of the holding in 4502.T has increased by JPY 5,758 (USD $37) compared to the previous valuation of Takeda Pharmaceutical Company Limited however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| 4503.T - Astellas Pharma Inc. | HOLD | 0 @ JPY 16.0657 | JPY 0 | The current share valuation price of 4503.T based on adjusted close was JPY 16.0657. The average price that 4503.T shares were previous bought at was JPY 11.9155. The current market price is 34.8% higher than average price they were purchased at. The value of the holding in 4503.T has increased by JPY 306,817 (USD $1,951) compared to the previous valuation of Astellas Pharma Inc. however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| 4507.T - Shionogi & Co., Ltd. | HOLD | 0 @ JPY 22.5908 | JPY 0 | The current share valuation price of 4507.T based on adjusted close was JPY 22.5908. The average price that 4507.T shares were previous bought at was JPY 17.4515. The current market price is 29.4% higher than average price they were purchased at. The value of the holding in 4507.T has increased by JPY 18,132 (USD $115) compared to the previous valuation of Shionogi & Co., Ltd. however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| 4519.T - Chugai Pharmaceutical Co., Ltd. | HOLD | 0 @ JPY 58.5526 | JPY 0 | The current share valuation price of 4519.T based on adjusted close was JPY 58.5526. The average price that 4519.T shares were previous bought at was JPY 49.3536. The current market price is 18.6% higher than average price they were purchased at. The value of the holding in 4519.T has increased by JPY 353,056 (USD $2,245) compared to the previous valuation of Chugai Pharmaceutical Co., Ltd. however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| 4523.T - Eisai Co., Ltd. | HOLD | 0 @ JPY 29.2763 | JPY 0 | The current share valuation price of 4523.T based on adjusted close was JPY 29.2763. The average price that 4523.T shares were previous bought at was JPY 30.1288. The current market price is -2.8% lower than average price they were purchased at. The value of the holding in 4523.T has increased by JPY 86,922 (USD $553) compared to the previous valuation of Eisai Co., Ltd. however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| 4543.T - Terumo Corporation | HOLD | 0 @ JPY 13.3453 | JPY 0 | The current share valuation price of 4543.T based on adjusted close was JPY 13.3453. The average price that 4543.T shares were previous bought at was JPY 15.6274. The current market price is -14.6% lower than average price they were purchased at. The value of the holding in 4543.T has increased by JPY 10,434 (USD $66) compared to the previous valuation of Terumo Corporation however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| 4568.T - Daiichi Sankyo Company, Limited | HOLD | 0 @ JPY 18.9401 | JPY 0 | The current share valuation price of 4568.T based on adjusted close was JPY 18.9401. The average price that 4568.T shares were previous bought at was JPY 23.0746. The current market price is -17.9% lower than average price they were purchased at. The value of the holding in 4568.T has increased by JPY 182,777 (USD $1,162) compared to the previous valuation of Daiichi Sankyo Company, Limited however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| 4578.T - Otsuka Holdings Co., Ltd. | HOLD | 0 @ JPY 61.6643 | JPY 0 | The current share valuation price of 4578.T based on adjusted close was JPY 61.6643. The average price that 4578.T shares were previous bought at was JPY 55.517. The current market price is 11.1% higher than average price they were purchased at. The value of the holding in 4578.T has increased by JPY 22,818 (USD $145) compared to the previous valuation of Otsuka Holdings Co., Ltd. however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| 6869.T - Sysmex Corporation | HOLD | 0 @ JPY 9.75555 | JPY 0 | The current share valuation price of 6869.T based on adjusted close was JPY 9.75555. The average price that 6869.T shares were previous bought at was JPY 11.1967. The current market price is -12.9% lower than average price they were purchased at. The value of the holding in 6869.T has increased by JPY 54,839 (USD $349) compared to the previous valuation of Sysmex Corporation however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| 7733.T - Olympus Corporation | HOLD | 0 @ JPY 12.4374 | JPY 0 | The current share valuation price of 7733.T based on adjusted close was JPY 12.4374. The average price that 7733.T shares were previous bought at was JPY 12.7281. The current market price is -2.3% lower than average price they were purchased at. The value of the holding in 7733.T has increased by JPY 12,503 (USD $80) compared to the previous valuation of Olympus Corporation however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| 7741.T - HOYA Corporation | HOLD | 0 @ JPY 175.703 | JPY 0 | The current share valuation price of 7741.T based on adjusted close was JPY 175.703. The average price that 7741.T shares were previous bought at was JPY 147.114. The current market price is 19.4% higher than average price they were purchased at. The value of the holding in 7741.T has increased by JPY 92,395 (USD $588) compared to the previous valuation of HOYA Corporation however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| A - Agilent Technologies Inc | HOLD | 0 @ USD 127.5 | USD 0 | The current share valuation price of A based on adjusted close was USD 127.5. The average price that A shares were previous bought at was USD 136.647. The current market price is -6.7% lower than average price they were purchased at. The value of the holding in A has fallen by USD 135,641 compared to the previous valuation of Agilent Technologies Inc |
| ABBV - AbbVie Inc | HOLD | 0 @ USD 223.26 | USD 0 | The current share valuation price of ABBV based on adjusted close was USD 223.26. The average price that ABBV shares were previous bought at was USD 211.499. The current market price is 5.6% higher than average price they were purchased at. The value of the holding in ABBV has fallen by USD 29,303 compared to the previous valuation of AbbVie Inc |
| ABT - Abbott Laboratories | HOLD | 0 @ USD 111.07 | USD 0 | The current share valuation price of ABT based on adjusted close was USD 111.07. The average price that ABT shares were previous bought at was USD 130.105. The current market price is -14.6% lower than average price they were purchased at. The value of the holding in ABT has increased by USD 24,866 compared to the previous valuation of Abbott Laboratories however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| ALC.SW - | HOLD | 0 @ CHF 78.4078 | CHF 0 | The current share valuation price of ALC.SW based on adjusted close was CHF 78.4078. The average price that ALC.SW shares were previous bought at was CHF 78.6947. The current market price is -0.4% lower than average price they were purchased at. The value of the holding in ALC.SW has increased by CHF 8,566 (USD $11,041) compared to the previous valuation of however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| ALNY - Alnylam Pharmaceuticals Inc | HOLD | 0 @ USD 320 | USD 0 | The current share valuation price of ALNY based on adjusted close was USD 320. The average price that ALNY shares were previous bought at was USD 415.922. The current market price is -23.1% lower than average price they were purchased at. The value of the holding in ALNY has fallen by USD 101,812 compared to the previous valuation of Alnylam Pharmaceuticals Inc |
| AMGN - Amgen Inc | HOLD | 0 @ USD 375.82 | USD 0 | The current share valuation price of AMGN based on adjusted close was USD 375.82. The average price that AMGN shares were previous bought at was USD 307.773. The current market price is 22.1% higher than average price they were purchased at. The value of the holding in AMGN has fallen by USD 366,444 compared to the previous valuation of Amgen Inc |
| ARGX.BR - Argenx SE | HOLD | 0 @ EUR 835.781 | EUR 0 | The current share valuation price of ARGX.BR based on adjusted close was EUR 835.781. The average price that ARGX.BR shares were previous bought at was EUR 846.415. The current market price is -1.3% lower than average price they were purchased at. The value of the holding in ARGX.BR has increased by EUR 73,707 (USD $87,164) compared to the previous valuation of Argenx SE however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| AZN.L - AstraZeneca PLC | HOLD | 0 @ GBP 189.981 | GBP 0 | The current share valuation price of AZN.L based on adjusted close was GBP 189.981. The average price that AZN.L shares were previous bought at was GBP 169.979. The current market price is 11.8% higher than average price they were purchased at. The value of the holding in AZN.L has fallen by GBP 345,891 (USD $470,722) compared to the previous valuation of AstraZeneca PLC |
| BAX - Baxter International Inc | HOLD | 0 @ USD 21.73 | USD 0 | The current share valuation price of BAX based on adjusted close was USD 21.73. The average price that BAX shares were previous bought at was USD 19.5094. The current market price is 11.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of Baxter International Inc however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| BAYN.DE - Bayer AG | HOLD | 0 @ EUR 55.131 | EUR 0 | The current share valuation price of BAYN.DE based on adjusted close was EUR 55.131. The average price that BAYN.DE shares were previous bought at was EUR 37.3213. The current market price is 47.7% higher than average price they were purchased at. The value of the holding in BAYN.DE has increased by EUR 23,597 (USD $27,905) compared to the previous valuation of Bayer AG however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| BDX - Becton Dickinson and Company | HOLD | 0 @ USD 207.39 | USD 0 | The current share valuation price of BDX based on adjusted close was USD 207.39. The average price that BDX shares were previous bought at was USD 189.573. The current market price is 9.4% higher than average price they were purchased at. The value of the holding in BDX has fallen by USD 18,497 compared to the previous valuation of Becton Dickinson and Company |
| BIIB - Biogen Inc | HOLD | 0 @ USD 193.81 | USD 0 | The current share valuation price of BIIB based on adjusted close was USD 193.81. The average price that BIIB shares were previous bought at was USD 174.144. The current market price is 11.3% higher than average price they were purchased at. The value of the holding in BIIB has fallen by USD 79,036 compared to the previous valuation of Biogen Inc |
| BIM.PA - BioMerieux | HOLD | 0 @ EUR 111.203 | EUR 0 | The current share valuation price of BIM.PA based on adjusted close was EUR 111.203. The average price that BIM.PA shares were previous bought at was EUR 127.068. The current market price is -12.5% lower than average price they were purchased at. The value of the holding in BIM.PA has fallen by EUR 2,333 (USD $2,759) compared to the previous valuation of BioMerieux |
| BMY - Bloomsbury Publishing Plc | HOLD | 0 @ USD 60.77 | USD 0 | The current share valuation price of BMY based on adjusted close was USD 60.77. The average price that BMY shares were previous bought at was USD 48.6815. The current market price is 24.8% higher than average price they were purchased at. The value of the holding in BMY has fallen by USD 180,163 compared to the previous valuation of Bloomsbury Publishing Plc |
| BSX - Boston Scientific Corporation | HOLD | 0 @ USD 74.12 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 74.12. The average price that BSX shares were previous bought at was USD 98.4451. The current market price is -24.7% lower than average price they were purchased at. The value of the holding in BSX has fallen by USD 85,325 compared to the previous valuation of Boston Scientific Corporation |
| BSX - MULSTRXSSXIMETFP | HOLD | 0 @ USD 74.12 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 74.12. The average price that BSX shares were previous bought at was USD 98.4451. The current market price is -24.7% lower than average price they were purchased at. The value of the holding in BSX has fallen by USD 85,325 compared to the previous valuation of MULSTRXSSXIMETFP |
| CAH - Cardinal Health Inc | HOLD | 0 @ USD 225.76 | USD 0 | The current share valuation price of CAH based on adjusted close was USD 225.76. The average price that CAH shares were previous bought at was USD 181.757. The current market price is 24.2% higher than average price they were purchased at. The value of the holding in CAH has fallen by USD 32,385 compared to the previous valuation of Cardinal Health Inc |
| CI - Cigna Corp | HOLD | 0 @ USD 294.4 | USD 0 | The current share valuation price of CI based on adjusted close was USD 294.4. The average price that CI shares were previous bought at was USD 284.35. The current market price is 3.5% higher than average price they were purchased at. The value of the holding in CI has increased by USD 101,339 compared to the previous valuation of Cigna Corp however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| CNC - Concurrent Technologies Plc | HOLD | 0 @ USD 38.04 | USD 0 | The current share valuation price of CNC based on adjusted close was USD 38.04. The average price that CNC shares were previous bought at was USD 39.7853. The current market price is -4.4% lower than average price they were purchased at. The value of the holding in CNC has fallen by USD 46,302 compared to the previous valuation of Concurrent Technologies Plc |
| COH.AX - | HOLD | 0 @ AUD 179.449 | AUD 0 | The current share valuation price of COH.AX based on adjusted close was AUD 179.449. The average price that COH.AX shares were previous bought at was AUD 181.315. The current market price is -1.0% lower than average price they were purchased at. The value of the holding in COH.AX has increased by AUD 130,274 (USD $91,631) compared to the previous valuation of however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| COLO-B.CO - | HOLD | 0 @ DKK 76.6974 | DKK 0 | The current share valuation price of COLO-B.CO based on adjusted close was DKK 76.6974. The average price that COLO-B.CO shares were previous bought at was DKK 89.5825. The current market price is -14.4% lower than average price they were purchased at. The value of the holding in COLO-B.CO has fallen by DKK 84,457 (USD $13,374) compared to the previous valuation of |
| COO - The Cooper Companies, Inc. Common Stock | HOLD | 0 @ USD 81.48 | USD 0 | The current share valuation price of COO based on adjusted close was USD 81.48. The average price that COO shares were previous bought at was USD 76.8475. The current market price is 6.0% higher than average price they were purchased at. The value of the holding in COO has fallen by USD 13,803 compared to the previous valuation of The Cooper Companies, Inc. Common Stock |
| COR - Cencora Inc. | HOLD | 0 @ USD 363.27 | USD 0 | The current share valuation price of COR based on adjusted close was USD 363.27. The average price that COR shares were previous bought at was USD 330.466. The current market price is 9.9% higher than average price they were purchased at. The value of the holding in COR has increased by USD 174,829 compared to the previous valuation of Cencora Inc. however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| CSL.AX - | HOLD | 0 @ AUD 127.873 | AUD 0 | The current share valuation price of CSL.AX based on adjusted close was AUD 127.873. The average price that CSL.AX shares were previous bought at was AUD 119.603. The current market price is 6.9% higher than average price they were purchased at. The value of the holding in CSL.AX has increased by AUD 43,026 (USD $30,263) compared to the previous valuation of however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| CVS - CVS Health Corp | HOLD | 0 @ USD 75.77 | USD 0 | The current share valuation price of CVS based on adjusted close was USD 75.77. The average price that CVS shares were previous bought at was USD 72.8444. The current market price is 4.0% higher than average price they were purchased at. The value of the holding in CVS has fallen by USD 229,625 compared to the previous valuation of CVS Health Corp |
| DEMANT.CO - | HOLD | 0 @ DKK 29.2439 | DKK 0 | The current share valuation price of DEMANT.CO based on adjusted close was DKK 29.2439. The average price that DEMANT.CO shares were previous bought at was DKK 35.0526. The current market price is -16.6% lower than average price they were purchased at. The value of the holding in DEMANT.CO has fallen by DKK 17,994 (USD $2,849) compared to the previous valuation of |
| DGX - Quest Diagnostics Incorporated | HOLD | 0 @ USD 191.25 | USD 0 | The current share valuation price of DGX based on adjusted close was USD 191.25. The average price that DGX shares were previous bought at was USD 180.242. The current market price is 6.1% higher than average price they were purchased at. The value of the holding in DGX has increased by USD 1,471 compared to the previous valuation of Quest Diagnostics Incorporated however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| DHR - Danaher Corporation | HOLD | 0 @ USD 216.66 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 216.66. The average price that DHR shares were previous bought at was USD 213.929. The current market price is 1.3% higher than average price they were purchased at. The value of the holding in DHR has increased by USD 2,756 compared to the previous valuation of Danaher Corporation however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| DHR - Danaher Corporation | HOLD | 0 @ USD 216.66 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 216.66. The average price that DHR shares were previous bought at was USD 213.929. The current market price is 1.3% higher than average price they were purchased at. The value of the holding in DHR has increased by USD 2,756 compared to the previous valuation of Danaher Corporation however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| DIM.PA - Sartorius Stedim Biotech | HOLD | 0 @ EUR 212.34 | EUR 0 | The current share valuation price of DIM.PA based on adjusted close was EUR 212.34. The average price that DIM.PA shares were previous bought at was EUR 228.27. The current market price is -7.0% lower than average price they were purchased at. The value of the holding in DIM.PA has increased by EUR 3,474 (USD $4,108) compared to the previous valuation of Sartorius Stedim Biotech however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| DXCM - DexCom Inc | HOLD | 0 @ USD 70.16 | USD 0 | The current share valuation price of DXCM based on adjusted close was USD 70.16. The average price that DXCM shares were previous bought at was USD 68.9354. The current market price is 1.8% higher than average price they were purchased at. The value of the holding in DXCM has increased by USD 2,635 compared to the previous valuation of DexCom Inc however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| EL.PA - EssilorLuxottica SA | HOLD | 0 @ EUR 303.53 | EUR 0 | The current share valuation price of EL.PA based on adjusted close was EUR 303.53. The average price that EL.PA shares were previous bought at was EUR 339.054. The current market price is -10.5% lower than average price they were purchased at. The value of the holding in EL.PA has increased by EUR 54,580 (USD $64,545) compared to the previous valuation of EssilorLuxottica SA however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| ELV - Elevance Health Inc | HOLD | 0 @ USD 327.5 | USD 0 | The current share valuation price of ELV based on adjusted close was USD 327.5. The average price that ELV shares were previous bought at was USD 343.941. The current market price is -4.8% lower than average price they were purchased at. The value of the holding in ELV has fallen by USD 471,047 compared to the previous valuation of Elevance Health Inc |
| ELV - Elevance Health Inc | HOLD | 0 @ USD 327.5 | USD 0 | The current share valuation price of ELV based on adjusted close was USD 327.5. The average price that ELV shares were previous bought at was USD 343.941. The current market price is -4.8% lower than average price they were purchased at. The value of the holding in ELV has fallen by USD 471,047 compared to the previous valuation of Elevance Health Inc |
| ERF.PA - Eurofins Scientific SE | HOLD | 0 @ EUR 80.0759 | EUR 0 | The current share valuation price of ERF.PA based on adjusted close was EUR 80.0759. The average price that ERF.PA shares were previous bought at was EUR 71.6347. The current market price is 11.8% higher than average price they were purchased at. The value of the holding in ERF.PA has fallen by EUR 1,510 (USD $1,786) compared to the previous valuation of Eurofins Scientific SE |
| EW - Edwards Lifesciences Corp | HOLD | 0 @ USD 76.8 | USD 0 | The current share valuation price of EW based on adjusted close was USD 76.8. The average price that EW shares were previous bought at was USD 81.586. The current market price is -5.9% lower than average price they were purchased at. The value of the holding in EW has fallen by USD 216,005 compared to the previous valuation of Edwards Lifesciences Corp |
| FME.DE - Fresenius Medical Care AG | HOLD | 0 @ EUR 47.3998 | EUR 0 | The current share valuation price of FME.DE based on adjusted close was EUR 47.3998. The average price that FME.DE shares were previous bought at was EUR 48.714. The current market price is -2.7% lower than average price they were purchased at. The value of the holding in FME.DE has fallen by EUR 4,245 (USD $5,020) compared to the previous valuation of Fresenius Medical Care AG |
| FPH.NZ - | HOLD | 0 @ NZD 23.7625 | NZD 0 | The current share valuation price of FPH.NZ based on adjusted close was NZD 23.7625. The average price that FPH.NZ shares were previous bought at was NZD 21.5706. The current market price is 10.2% higher than average price they were purchased at. The value of the holding in FPH.NZ has fallen by NZD 3,412 (USD $2,058) compared to the previous valuation of |
| FRE.DE - Fresenius SE & Co KGaA | HOLD | 0 @ EUR 59.5863 | EUR 0 | The current share valuation price of FRE.DE based on adjusted close was EUR 59.5863. The average price that FRE.DE shares were previous bought at was EUR 54.0691. The current market price is 10.2% higher than average price they were purchased at. The value of the holding in FRE.DE has increased by EUR 8,643 (USD $10,221) compared to the previous valuation of Fresenius SE & Co KGaA however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| GALD.SW - | HOLD | 0 @ CHF 194.976 | CHF 0 | The current share valuation price of GALD.SW based on adjusted close was CHF 194.976. The average price that GALD.SW shares were previous bought at was CHF 188.255. The current market price is 3.6% higher than average price they were purchased at. The value of the holding in GALD.SW has increased by CHF 61,376 (USD $79,110) compared to the previous valuation of however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| GEHC - GE HealthCare Technologies Inc. | HOLD | 0 @ USD 79.08 | USD 0 | The current share valuation price of GEHC based on adjusted close was USD 79.08. The average price that GEHC shares were previous bought at was USD 79.0142. The current market price is 0.1% higher than average price they were purchased at. The value of the holding in GEHC has fallen by USD 18,116 compared to the previous valuation of GE HealthCare Technologies Inc. |
| GILD - Guild Esports Plc | HOLD | 0 @ USD 151.68 | USD 0 | The current share valuation price of GILD based on adjusted close was USD 151.68. The average price that GILD shares were previous bought at was USD 119.488. The current market price is 26.9% higher than average price they were purchased at. The value of the holding in GILD has fallen by USD 141,446 compared to the previous valuation of Guild Esports Plc |
| GMAB.CO - | HOLD | 0 @ DKK 307.985 | DKK 0 | The current share valuation price of GMAB.CO based on adjusted close was DKK 307.985. The average price that GMAB.CO shares were previous bought at was DKK 296.475. The current market price is 3.9% higher than average price they were purchased at. The value of the holding in GMAB.CO has fallen by DKK 28,765 (USD $4,555) compared to the previous valuation of |
| GRF.MC - Grifols SA | HOLD | 0 @ EUR 13.1752 | EUR 0 | The current share valuation price of GRF.MC based on adjusted close was EUR 13.1752. The average price that GRF.MC shares were previous bought at was EUR 12.988. The current market price is 1.4% higher than average price they were purchased at. The value of the holding in GRF.MC has increased by EUR 8,424 (USD $9,962) compared to the previous valuation of Grifols SA however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| GSK.L - GlaxoSmithKline PLC | HOLD | 0 @ GBP 29.534 | GBP 0 | The current share valuation price of GSK.L based on adjusted close was GBP 29.534. The average price that GSK.L shares were previous bought at was GBP 23.5379. The current market price is 25.5% higher than average price they were purchased at. The value of the holding in GSK.L has fallen by GBP 97,284 (USD $132,393) compared to the previous valuation of GlaxoSmithKline PLC |
| HCA - HCA Holdings Inc | HOLD | 0 @ USD 497.54 | USD 0 | The current share valuation price of HCA based on adjusted close was USD 497.54. The average price that HCA shares were previous bought at was USD 455.867. The current market price is 9.1% higher than average price they were purchased at. The value of the holding in HCA has fallen by USD 19,443 compared to the previous valuation of HCA Holdings Inc |
| HIK.L - | HOLD | 0 @ GBP 20.9707 | GBP 0 | The current share valuation price of HIK.L based on adjusted close was GBP 20.9707. The average price that HIK.L shares were previous bought at was GBP 22.2686. The current market price is -5.8% lower than average price they were purchased at. The value of the holding in HIK.L has increased by GBP 86 (USD $117) compared to the previous valuation of however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| HLN.L - Haleon PLC | HOLD | 0 @ GBP 5.36784 | GBP 0 | The current share valuation price of HLN.L based on adjusted close was GBP 5.36784. The average price that HLN.L shares were previous bought at was GBP 4.91084. The current market price is 9.3% higher than average price they were purchased at. The value of the holding in HLN.L has fallen by GBP 18,879 (USD $25,692) compared to the previous valuation of Haleon PLC |
| HOLX - Hologic Inc | HOLD | 0 @ USD 75.02 | USD 0 | The current share valuation price of HOLX based on adjusted close was USD 75.02. The average price that HOLX shares were previous bought at was USD 72.0253. The current market price is 4.2% higher than average price they were purchased at. The value of the holding in HOLX has increased by USD 19,359 compared to the previous valuation of Hologic Inc however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| HUM - Hummingbird Resources PLC | HOLD | 0 @ USD 189.49 | USD 0 | The current share valuation price of HUM based on adjusted close was USD 189.49. The average price that HUM shares were previous bought at was USD 265.131. The current market price is -28.5% lower than average price they were purchased at. The value of the holding in HUM has fallen by USD 92,053 compared to the previous valuation of Hummingbird Resources PLC |
| HUM - Humana Inc | HOLD | 0 @ USD 189.49 | USD 0 | The current share valuation price of HUM based on adjusted close was USD 189.49. The average price that HUM shares were previous bought at was USD 265.131. The current market price is -28.5% lower than average price they were purchased at. The value of the holding in HUM has fallen by USD 92,053 compared to the previous valuation of Humana Inc |
| IDXX - IDEXX Laboratories Inc | HOLD | 0 @ USD 639.79 | USD 0 | The current share valuation price of IDXX based on adjusted close was USD 639.79. The average price that IDXX shares were previous bought at was USD 649.213. The current market price is -1.5% lower than average price they were purchased at. The value of the holding in IDXX has fallen by USD 86,355 compared to the previous valuation of IDEXX Laboratories Inc |
| ILMN - Illumina Inc | HOLD | 0 @ USD 117.25 | USD 0 | The current share valuation price of ILMN based on adjusted close was USD 117.25. The average price that ILMN shares were previous bought at was USD 119.733. The current market price is -2.1% lower than average price they were purchased at. The value of the holding in ILMN has fallen by USD 9,502 compared to the previous valuation of Illumina Inc |
| INCY - Incyte Corporation | HOLD | 0 @ USD 109.03 | USD 0 | The current share valuation price of INCY based on adjusted close was USD 109.03. The average price that INCY shares were previous bought at was USD 103.133. The current market price is 5.7% higher than average price they were purchased at. The value of the holding in INCY has increased by USD 9,379 compared to the previous valuation of Incyte Corporation however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| INSM - Insmed Inc | HOLD | 0 @ USD 149.54 | USD 0 | The current share valuation price of INSM based on adjusted close was USD 149.54. The average price that INSM shares were previous bought at was USD 182.2. The current market price is -17.9% lower than average price they were purchased at. The value of the holding in INSM has fallen by USD 4,300 compared to the previous valuation of Insmed Inc |
| IPN.PA - Ipsen SA | HOLD | 0 @ EUR 164.273 | EUR 0 | The current share valuation price of IPN.PA based on adjusted close was EUR 164.273. The average price that IPN.PA shares were previous bought at was EUR 138.353. The current market price is 18.7% higher than average price they were purchased at. The value of the holding in IPN.PA has increased by EUR 8,668 (USD $10,251) compared to the previous valuation of Ipsen SA however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| IQV - IQVIA Holdings Inc | HOLD | 0 @ USD 192.67 | USD 0 | The current share valuation price of IQV based on adjusted close was USD 192.67. The average price that IQV shares were previous bought at was USD 209.611. The current market price is -8.1% lower than average price they were purchased at. The value of the holding in IQV has increased by USD 252,551 compared to the previous valuation of IQVIA Holdings Inc however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| ISRG - Intuitive Surgical Inc | HOLD | 0 @ USD 492.84 | USD 0 | The current share valuation price of ISRG based on adjusted close was USD 492.84. The average price that ISRG shares were previous bought at was USD 542.778. The current market price is -9.2% lower than average price they were purchased at. The value of the holding in ISRG has increased by USD 135,551 compared to the previous valuation of Intuitive Surgical Inc however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| JNJ - Johnson & Johnson | HOLD | 0 @ USD 238.64 | USD 0 | The current share valuation price of JNJ based on adjusted close was USD 238.64. The average price that JNJ shares were previous bought at was USD 177.042. The current market price is 34.8% higher than average price they were purchased at. The value of the holding in JNJ has fallen by USD 242,017 compared to the previous valuation of Johnson & Johnson |
| LH - Laboratory Corporation of America Holdings | HOLD | 0 @ USD 274.01 | USD 0 | The current share valuation price of LH based on adjusted close was USD 274.01. The average price that LH shares were previous bought at was USD 260.743. The current market price is 5.1% higher than average price they were purchased at. The value of the holding in LH has fallen by USD 6,632 compared to the previous valuation of Laboratory Corporation of America Holdings |
| LLY - Eli Lilly and Company | HOLD | 0 @ USD 1044.67 | USD 0 | The current share valuation price of LLY based on adjusted close was USD 1044.67. The average price that LLY shares were previous bought at was USD 918.719. The current market price is 13.7% higher than average price they were purchased at. The value of the holding in LLY has fallen by USD 1,053,145 compared to the previous valuation of Eli Lilly and Company |
| LONN.SW - | HOLD | 0 @ CHF 673.148 | CHF 0 | The current share valuation price of LONN.SW based on adjusted close was CHF 673.148. The average price that LONN.SW shares were previous bought at was CHF 676.718. The current market price is -0.5% lower than average price they were purchased at. The value of the holding in LONN.SW has increased by CHF 10,768 (USD $13,879) compared to the previous valuation of however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| MCK - McKesson Corporation | HOLD | 0 @ USD 962.32 | USD 0 | The current share valuation price of MCK based on adjusted close was USD 962.32. The average price that MCK shares were previous bought at was USD 797.826. The current market price is 20.6% higher than average price they were purchased at. The value of the holding in MCK has increased by USD 251,686 compared to the previous valuation of McKesson Corporation however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| MDT - Medtronic PLC | HOLD | 0 @ USD 101.65 | USD 0 | The current share valuation price of MDT based on adjusted close was USD 101.65. The average price that MDT shares were previous bought at was USD 97.5886. The current market price is 4.2% higher than average price they were purchased at. The value of the holding in MDT has fallen by USD 50,357 compared to the previous valuation of Medtronic PLC |
| MRK - Marks Electrical Group PLC | HOLD | 0 @ USD 117.65 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 117.65. The average price that MRK shares were previous bought at was USD 87.9772. The current market price is 33.7% higher than average price they were purchased at. The value of the holding in MRK has fallen by USD 884,214 compared to the previous valuation of Marks Electrical Group PLC |
| MRK - Merck & Company Inc | HOLD | 0 @ USD 117.65 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 117.65. The average price that MRK shares were previous bought at was USD 87.9772. The current market price is 33.7% higher than average price they were purchased at. The value of the holding in MRK has fallen by USD 884,214 compared to the previous valuation of Merck & Company Inc |
| MRK.DE - Merck KGaA | HOLD | 0 @ EUR 146.881 | EUR 0 | The current share valuation price of MRK.DE based on adjusted close was EUR 146.881. The average price that MRK.DE shares were previous bought at was EUR 137.019. The current market price is 7.2% higher than average price they were purchased at. The value of the holding in MRK.DE has increased by EUR 10,616 (USD $12,554) compared to the previous valuation of Merck KGaA however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| MTD - Mettler-Toledo International Inc | HOLD | 0 @ USD 1380.88 | USD 0 | The current share valuation price of MTD based on adjusted close was USD 1380.88. The average price that MTD shares were previous bought at was USD 1455.71. The current market price is -5.1% lower than average price they were purchased at. The value of the holding in MTD has increased by USD 20,168 compared to the previous valuation of Mettler-Toledo International Inc however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| MTD - AMUNDI EUR GOV 710 | HOLD | 0 @ USD 1380.88 | USD 0 | The current share valuation price of MTD based on adjusted close was USD 1380.88. The average price that MTD shares were previous bought at was USD 1455.71. The current market price is -5.1% lower than average price they were purchased at. The value of the holding in MTD has increased by USD 20,168 compared to the previous valuation of AMUNDI EUR GOV 710 however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 139.56 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 139.56. The average price that NBIX shares were previous bought at was USD 142.165. The current market price is -1.8% lower than average price they were purchased at. The value of the holding in NBIX has fallen by USD 3,758 compared to the previous valuation of Neurocrine Biosciences Inc |
| NOVO-B.CO - Novo Nordisk A/S | HOLD | 0 @ DKK 49.5902 | DKK 0 | The current share valuation price of NOVO-B.CO based on adjusted close was DKK 49.5902. The average price that NOVO-B.CO shares were previous bought at was DKK 54.4696. The current market price is -9.0% lower than average price they were purchased at. The value of the holding in NOVO-B.CO has increased by DKK 991,666 (USD $157,031) compared to the previous valuation of Novo Nordisk A/S however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| NTRA - Natera Inc | HOLD | 0 @ USD 210.58 | USD 0 | The current share valuation price of NTRA based on adjusted close was USD 210.58. The average price that NTRA shares were previous bought at was USD 194.07. The current market price is 8.5% higher than average price they were purchased at. The value of the holding in NTRA has increased by USD 28,230 compared to the previous valuation of Natera Inc however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| ORNBV.HE - Orion Oyj | HOLD | 0 @ EUR 88.5099 | EUR 0 | The current share valuation price of ORNBV.HE based on adjusted close was EUR 88.5099. The average price that ORNBV.HE shares were previous bought at was EUR 70.47. The current market price is 25.6% higher than average price they were purchased at. The value of the holding in ORNBV.HE has increased by EUR 6,830 (USD $8,077) compared to the previous valuation of Orion Oyj however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| PFE - Pfizer Inc | HOLD | 0 @ USD 27.05 | USD 0 | The current share valuation price of PFE based on adjusted close was USD 27.05. The average price that PFE shares were previous bought at was USD 24.9116. The current market price is 8.6% higher than average price they were purchased at. The value of the holding in PFE has fallen by USD 51,370 compared to the previous valuation of Pfizer Inc |
| PHIA.AS - Koninklijke Philips NV | HOLD | 0 @ EUR 29.3882 | EUR 0 | The current share valuation price of PHIA.AS based on adjusted close was EUR 29.3882. The average price that PHIA.AS shares were previous bought at was EUR 27.0173. The current market price is 8.8% higher than average price they were purchased at. The value of the holding in PHIA.AS has increased by EUR 1,774 (USD $2,098) compared to the previous valuation of Koninklijke Philips NV however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| PME.AX - | HOLD | 0 @ AUD 114.262 | AUD 0 | The current share valuation price of PME.AX based on adjusted close was AUD 114.262. The average price that PME.AX shares were previous bought at was AUD 164.271. The current market price is -30.4% lower than average price they were purchased at. The value of the holding in PME.AX has increased by AUD 7,004 (USD $4,926) compared to the previous valuation of however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| PODD - Insulet Corporation | HOLD | 0 @ USD 245.57 | USD 0 | The current share valuation price of PODD based on adjusted close was USD 245.57. The average price that PODD shares were previous bought at was USD 322.758. The current market price is -23.9% lower than average price they were purchased at. The value of the holding in PODD has increased by USD 13,016 compared to the previous valuation of Insulet Corporation however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| REC.MI - Recordati Industria Chimica e Farmaceutica SpA | HOLD | 0 @ EUR 56.1556 | EUR 0 | The current share valuation price of REC.MI based on adjusted close was EUR 56.1556. The average price that REC.MI shares were previous bought at was EUR 57.7774. The current market price is -2.8% lower than average price they were purchased at. The value of the holding in REC.MI has increased by EUR 2,150 (USD $2,543) compared to the previous valuation of Recordati Industria Chimica e Farmaceutica SpA however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| REGN - Regeneron Pharmaceuticals Inc | HOLD | 0 @ USD 780.28 | USD 0 | The current share valuation price of REGN based on adjusted close was USD 780.28. The average price that REGN shares were previous bought at was USD 722.712. The current market price is 8.0% higher than average price they were purchased at. The value of the holding in REGN has fallen by USD 42,159 compared to the previous valuation of Regeneron Pharmaceuticals Inc |
| RMD - ResMed Inc | HOLD | 0 @ USD 275.96 | USD 0 | The current share valuation price of RMD based on adjusted close was USD 275.96. The average price that RMD shares were previous bought at was USD 253.496. The current market price is 8.9% higher than average price they were purchased at. The value of the holding in RMD has increased by USD 21,265 compared to the previous valuation of ResMed Inc however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| RO.SW - | HOLD | 0 @ CHF 473.736 | CHF 0 | The current share valuation price of RO.SW based on adjusted close was CHF 473.736. The average price that RO.SW shares were previous bought at was CHF 355.54. The current market price is 33.2% higher than average price they were purchased at. The value of the holding in RO.SW has increased by CHF 38,373 (USD $49,461) compared to the previous valuation of however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| ROG.SW - | HOLD | 0 @ CHF 461.729 | CHF 0 | The current share valuation price of ROG.SW based on adjusted close was CHF 461.729. The average price that ROG.SW shares were previous bought at was CHF 370.477. The current market price is 24.6% higher than average price they were purchased at. The value of the holding in ROG.SW has increased by CHF 107,995 (USD $139,199) compared to the previous valuation of however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| RPRX - Royalty Pharma Plc | HOLD | 0 @ USD 44.05 | USD 0 | The current share valuation price of RPRX based on adjusted close was USD 44.05. The average price that RPRX shares were previous bought at was USD 37.9968. The current market price is 15.9% higher than average price they were purchased at. The value of the holding in RPRX has fallen by USD 6,067 compared to the previous valuation of Royalty Pharma Plc |
| SAN.PA - Sanofi SA | HOLD | 0 @ EUR 95.6455 | EUR 0 | The current share valuation price of SAN.PA based on adjusted close was EUR 95.6455. The average price that SAN.PA shares were previous bought at was EUR 98.2932. The current market price is -2.7% lower than average price they were purchased at. The value of the holding in SAN.PA has increased by EUR 43,076 (USD $50,941) compared to the previous valuation of Sanofi SA however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| SDZ.SW - | HOLD | 0 @ CHF 82.4013 | CHF 0 | The current share valuation price of SDZ.SW based on adjusted close was CHF 82.4013. The average price that SDZ.SW shares were previous bought at was CHF 63.8739. The current market price is 29.0% higher than average price they were purchased at. The value of the holding in SDZ.SW has increased by CHF 32,805 (USD $42,284) compared to the previous valuation of however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| SHL.AX - | HOLD | 0 @ AUD 15.5827 | AUD 0 | The current share valuation price of SHL.AX based on adjusted close was AUD 15.5827. The average price that SHL.AX shares were previous bought at was AUD 15.1239. The current market price is 3.0% higher than average price they were purchased at. The value of the holding in SHL.AX has increased by AUD 3,873 (USD $2,724) compared to the previous valuation of however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| SHL.DE - Siemens Healthineers AG | HOLD | 0 @ EUR 48.603 | EUR 0 | The current share valuation price of SHL.DE based on adjusted close was EUR 48.603. The average price that SHL.DE shares were previous bought at was EUR 53.0462. The current market price is -8.4% lower than average price they were purchased at. The value of the holding in SHL.DE has fallen by EUR 2,844 (USD $3,363) compared to the previous valuation of Siemens Healthineers AG |
| SIG.AX - | HOLD | 0 @ AUD 2.21192 | AUD 0 | The current share valuation price of SIG.AX based on adjusted close was AUD 2.21192. The average price that SIG.AX shares were previous bought at was AUD 1.90932. The current market price is 15.8% higher than average price they were purchased at. The value of the holding in SIG.AX has increased by AUD 14,866 (USD $10,456) compared to the previous valuation of however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| SN.L - Smith & Nephew PLC | HOLD | 0 @ GBP 17.414 | GBP 0 | The current share valuation price of SN.L based on adjusted close was GBP 17.414. The average price that SN.L shares were previous bought at was GBP 16.891. The current market price is 3.1% higher than average price they were purchased at. The value of the holding in SN.L has increased by GBP 3,495 (USD $4,756) compared to the previous valuation of Smith & Nephew PLC however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| SOBI.ST - | HOLD | 0 @ SEK 44.372 | SEK 0 | The current share valuation price of SOBI.ST based on adjusted close was SEK 44.372. The average price that SOBI.ST shares were previous bought at was SEK 33.7135. The current market price is 31.6% higher than average price they were purchased at. The value of the holding in SOBI.ST has increased by SEK 7,362 (USD $818) compared to the previous valuation of however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| SOLV - Solventum Corp. | HOLD | 0 @ USD 78.07 | USD 0 | The current share valuation price of SOLV based on adjusted close was USD 78.07. The average price that SOLV shares were previous bought at was USD 75.621. The current market price is 3.2% higher than average price they were purchased at. The value of the holding in SOLV has fallen by USD 236 compared to the previous valuation of Solventum Corp. |
| SOON.SW - | HOLD | 0 @ CHF 267.406 | CHF 0 | The current share valuation price of SOON.SW based on adjusted close was CHF 267.406. The average price that SOON.SW shares were previous bought at was CHF 269.34. The current market price is -0.7% lower than average price they were purchased at. The value of the holding in SOON.SW has increased by CHF 47,001 (USD $60,582) compared to the previous valuation of however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| SRT3.DE - Sartorius AG | HOLD | 0 @ EUR 277.204 | EUR 0 | The current share valuation price of SRT3.DE based on adjusted close was EUR 277.204. The average price that SRT3.DE shares were previous bought at was EUR 269.167. The current market price is 3.0% higher than average price they were purchased at. The value of the holding in SRT3.DE has fallen by EUR 47,494 (USD $56,165) compared to the previous valuation of Sartorius AG |
| STE - STERIS plc | HOLD | 0 @ USD 245.4 | USD 0 | The current share valuation price of STE based on adjusted close was USD 245.4. The average price that STE shares were previous bought at was USD 248.371. The current market price is -1.2% lower than average price they were purchased at. The value of the holding in STE has fallen by USD 264,613 compared to the previous valuation of STERIS plc |
| STMN.SW - | HOLD | 0 @ CHF 129.357 | CHF 0 | The current share valuation price of STMN.SW based on adjusted close was CHF 129.357. The average price that STMN.SW shares were previous bought at was CHF 121.166. The current market price is 6.8% higher than average price they were purchased at. The value of the holding in STMN.SW has increased by CHF 7,040 (USD $9,074) compared to the previous valuation of however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| SYK - Stryker Corporation | HOLD | 0 @ USD 356.08 | USD 0 | The current share valuation price of SYK based on adjusted close was USD 356.08. The average price that SYK shares were previous bought at was USD 366.946. The current market price is -3.0% lower than average price they were purchased at. The value of the holding in SYK has fallen by USD 41,519 compared to the previous valuation of Stryker Corporation |
| TEVA - Teva Pharma Industries Ltd ADR | HOLD | 0 @ USD 34.47 | USD 0 | The current share valuation price of TEVA based on adjusted close was USD 34.47. The average price that TEVA shares were previous bought at was USD 23.4264. The current market price is 47.1% higher than average price they were purchased at. The value of the holding in TEVA has fallen by USD 6,192 compared to the previous valuation of Teva Pharma Industries Ltd ADR |
| TMO - Time Out Group plc | HOLD | 0 @ USD 546.76 | USD 0 | The current share valuation price of TMO based on adjusted close was USD 546.76. The average price that TMO shares were previous bought at was USD 500.452. The current market price is 9.3% higher than average price they were purchased at. The value of the holding in TMO has increased by USD 101,028 compared to the previous valuation of Time Out Group plc however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| UCB.BR - UCB SA | HOLD | 0 @ EUR 317.23 | EUR 0 | The current share valuation price of UCB.BR based on adjusted close was EUR 317.23. The average price that UCB.BR shares were previous bought at was EUR 265.271. The current market price is 19.6% higher than average price they were purchased at. The value of the holding in UCB.BR has increased by EUR 193,026 (USD $228,268) compared to the previous valuation of UCB SA however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| UNH - UnitedHealth Group Incorporated | HOLD | 0 @ USD 275.7 | USD 0 | The current share valuation price of UNH based on adjusted close was USD 275.7. The average price that UNH shares were previous bought at was USD 324.259. The current market price is -15.0% lower than average price they were purchased at. The value of the holding in UNH has fallen by USD 77,283 compared to the previous valuation of UnitedHealth Group Incorporated |
| UTHR - United Therapeutics Corporation | HOLD | 0 @ USD 473.12 | USD 0 | The current share valuation price of UTHR based on adjusted close was USD 473.12. The average price that UTHR shares were previous bought at was USD 454.69. The current market price is 4.1% higher than average price they were purchased at. The value of the holding in UTHR has fallen by USD 13,415 compared to the previous valuation of United Therapeutics Corporation |
| VEEV - Veeva Systems Inc Class A | HOLD | 0 @ USD 184.61 | USD 0 | The current share valuation price of VEEV based on adjusted close was USD 184.61. The average price that VEEV shares were previous bought at was USD 256.643. The current market price is -28.1% lower than average price they were purchased at. The value of the holding in VEEV has increased by USD 31,606 compared to the previous valuation of Veeva Systems Inc Class A however if the holding was sold on 2026-02-09 this would crystalise an overall loss. |
| VRTX - Vertex Pharmaceuticals Inc | HOLD | 0 @ USD 470.87 | USD 0 | The current share valuation price of VRTX based on adjusted close was USD 470.87. The average price that VRTX shares were previous bought at was USD 437.561. The current market price is 7.6% higher than average price they were purchased at. The value of the holding in VRTX has fallen by USD 259,659 compared to the previous valuation of Vertex Pharmaceuticals Inc |
| WAT - Waters Corporation | HOLD | 0 @ USD 328.14 | USD 0 | The current share valuation price of WAT based on adjusted close was USD 328.14. The average price that WAT shares were previous bought at was USD 358.742. The current market price is -8.5% lower than average price they were purchased at. The value of the holding in WAT has fallen by USD 996,297 compared to the previous valuation of Waters Corporation |
| WAT - MULETFWATIMETFP | HOLD | 0 @ USD 328.14 | USD 0 | The current share valuation price of WAT based on adjusted close was USD 328.14. The average price that WAT shares were previous bought at was USD 358.742. The current market price is -8.5% lower than average price they were purchased at. The value of the holding in WAT has fallen by USD 996,297 compared to the previous valuation of MULETFWATIMETFP |
| WST - West Pharmaceutical Services Inc | HOLD | 0 @ USD 248.93 | USD 0 | The current share valuation price of WST based on adjusted close was USD 248.93. The average price that WST shares were previous bought at was USD 266.969. The current market price is -6.8% lower than average price they were purchased at. The value of the holding in WST has fallen by USD 37 compared to the previous valuation of West Pharmaceutical Services Inc |
| ZBH - Zimmer Biomet Holdings Inc | HOLD | 0 @ USD 89.7299 | USD 0 | The current share valuation price of ZBH based on adjusted close was USD 89.7299. The average price that ZBH shares were previous bought at was USD 94.1018. The current market price is -4.6% lower than average price they were purchased at. The value of the holding in ZBH has fallen by USD 933 compared to the previous valuation of Zimmer Biomet Holdings Inc |
| ZTS - Zoetis Inc | HOLD | 0 @ USD 127.3 | USD 0 | The current share valuation price of ZTS based on adjusted close was USD 127.3. The average price that ZTS shares were previous bought at was USD 132.244. The current market price is -3.7% lower than average price they were purchased at. The value of the holding in ZTS has fallen by USD 12,388 compared to the previous valuation of Zoetis Inc |